Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.
Kristen M KryskoJennifer S GravesMary RenselBianca Weinstock-GuttmanAlice RutatangwaGregory AaenAnita BelmanLeslie BensonTanuja ChitinisMark GormanManu S GoyalYolanda HarrisLauren KruppTimothy LotzeSoe MarManikum MoodleyJayne NessMoses RodriguezJohn RoseTeri SchreinerJan-Mendelt TillemaMichael WaltzT Charles CasperEmmanuelle Waubantnull nullPublished in: Annals of neurology (2020)
Initial treatment of pediatric MS/CIS with newer DMTs led to better disease activity control compared to injectables, supporting greater effectiveness of newer therapies. Long-term safety data for newer DMTs are required. ANN NEUROL 2020 ANN NEUROL 2020;88:42-55.
Keyphrases
- disease activity
- multiple sclerosis
- rheumatoid arthritis
- systemic lupus erythematosus
- randomized controlled trial
- rheumatoid arthritis patients
- systematic review
- ankylosing spondylitis
- juvenile idiopathic arthritis
- mass spectrometry
- electronic health record
- ms ms
- white matter
- machine learning
- deep learning
- smoking cessation